Expansion of peripheral Tregs following low-dose IL-2 therapy was confirmed in a subsequent study in which five patients with refractory SLE received daily subcutaneous injections of 1.5 million IU aldesleukin for five consecutive days. Here, IL2 is linked to systemic lupus erythematosus.